Li DK - Search Results

1

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. Goodin DS, et al. Among authors: li dk. Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15. Mult Scler. 2019. PMID: 29761737

2

Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology.

Laule C, Vavasour IM, Leung E, Li DK, Kozlowski P, Traboulsee AL, Oger J, Mackay AL, Moore GR. Laule C, et al. Among authors: li dk. Mult Scler. 2011 Feb;17(2):144-50. doi: 10.1177/1352458510384008. Epub 2010 Oct 21. Mult Scler. 2011. PMID: 20965961

3

Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.

Vavasour IM, Huijskens SC, Li DK, Traboulsee AL, Mädler B, Kolind SH, Rauscher A, Moore GW, MacKay AL, Laule C. Vavasour IM, et al. Among authors: li dk. Mult Scler. 2018 Oct;24(12):1557-1568. doi: 10.1177/1352458517723717. Epub 2017 Aug 7. Mult Scler. 2018. PMID: 28782447

4

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.

Vavasour IM, Tam R, Li DK, Laule C, Taylor C, Kolind SH, MacKay AL, Javed A, Traboulsee A. Vavasour IM, et al. Among authors: li dk. Mult Scler. 2019 May;25(6):811-818. doi: 10.1177/1352458518770085. Epub 2018 Apr 17. Mult Scler. 2019. PMID: 29663845

5

The role of MRI in the diagnosis of multiple sclerosis.

Traboulsee AL, Li DK. Traboulsee AL, et al. Among authors: li dk. Adv Neurol. 2006;98:125-46. Adv Neurol. 2006. PMID: 16400831 Review.

6

The use of MRI as an outcome measure in clinical trials.

Li DK, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D. Li DK, et al. Among authors: li mj. Adv Neurol. 2006;98:203-26. Adv Neurol. 2006. PMID: 16400836 Review.

7

Conventional MR imaging.

Traboulsee A, Li DK. Traboulsee A, et al. Among authors: li dk. Neuroimaging Clin N Am. 2008 Nov;18(4):651-73, x. doi: 10.1016/j.nic.2008.07.001. Neuroimaging Clin N Am. 2008. PMID: 19068407 Review.

8

Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials.

Dong J, Zhao Y, Petkau AJ, Li DK, Riddehough A, Traboulsee A. Dong J, et al. Among authors: li dk. Mult Scler. 2015 Jan;21(1):101-4. doi: 10.1177/1352458514533846. Epub 2014 May 22. Mult Scler. 2015. PMID: 24852923

9

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.

Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A. Traboulsee A, et al. BMC Neurol. 2018 May 11;18(1):68. doi: 10.1186/s12883-018-1066-8. BMC Neurol. 2018. PMID: 29751787 Free PMC article. Clinical Trial.

10

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.

Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A. Traboulsee A, et al. BMC Neurol. 2018 Sep 14;18(1):143. doi: 10.1186/s12883-018-1145-x. BMC Neurol. 2018. PMID: 30217172 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

509 results

Search Page